Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy

Wayne State University/Harper Hospital, Detroit, Michigan.

OBJECTIVES. This study was undertaken to characterize the outcome of survivors of ventricular fibrillation with no or minimal structural heart disease who received an implantable cardioverter-defibrillator. BACKGROUND. The prognosis among survivors of ventricular fibrillation with minimal or no structural cardiac abnormalities remains unclear. Since the advent of implantable cardioverter-defibrillators, this question takes on added importance. METHODS. This 10-center retrospective study provided information on 28 survivors of ventricular fibrillation (mean age 42 years) with minimal or no structural abnormalities who were treated with an implantable cardioverter-defibrillator. RESULTS. Ventricular tachyarrhythmias (polymorphic in all but one patient) were induced during baseline programmed stimulation in 39% of patients. During a median 30.6-month follow-up period after implantable cardioverter-defibrillator implantation, there were no cardiac deaths and two noncardiac deaths. Sixteen patients experienced 36 shock episodes (total 88 shocks). The majority of shocks were classified as "indeterminate"; one patient received 47 "spurious" shocks during one shock episode and each of four patients received one "appropriate" shock. Ventricular arrhythmias were not inducible in any of these latter four patients. CONCLUSIONS. Survivors of ventricular fibrillation with minimal or no structural cardiac abnormalities receiving an implantable cardioverter-defibrillator have an excellent 3-year survival rate. The occurrence, albeit infrequent, of appropriate implantable cardioverter-defibrillator shocks in this group suggests that these patients have a potential risk of recurrent cardiac arrest whose fatal outcome may be avoided by implantable cardioverter-defibrillator therapy.

This article has been cited by other articles:

				M. Haissaguerre, M. Shoda, P. Jais, A. Nogami, D. C. Shah, J. Kautzner, T. Arentz, D. Kalushe, D. Lamaison, M. Griffith, et al. Mapping and Ablation of Idiopathic Ventricular Fibrillation Circulation, August 20, 2002; 106(8): 962 - 967. [Abstract] [Full Text] [PDF]

				G. Gronefeld and S. H Hohnloser What do implantable cardioverter/defibrillators teach us about the mechanisms of sudden cardiac death? Cardiovasc Res, May 1, 2001; 50(2): 232 - 241. [Abstract] [Full Text] [PDF]

				C.A Remme, E.F.D Wever, A.A.M Wilde, R Derksen, and R.N.W Hauer Diagnosis and long-term follow-up of the Brugada syndrome in patients with idiopathic ventricular fibrillation Eur. Heart J., March 1, 2001; 22(5): 400 - 409. [Abstract] [PDF]

				M. Kakishita, T. Kurita, K. Matsuo, A. Taguchi, K. Suyama, W. Shimizu, N. Aihara, S. Kamakura, F. Yamamoto, J. Kobayashi, et al. Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1646 - 1653. [Abstract] [Full Text] [PDF]

				F. E. Marchlinski Predicting Arrhythmic Death : A Plea for Standardized Reporting Techniques and Data Based on Continuous Electrocardiographic Monitoring Circulation, September 16, 1997; 96(6): 1713 - 1716. [Full Text]

				A. E. Epstein, W. M. Miles, D. G. Benditt, A. J. Camm, E. J. Darling, P. L. Friedman, A. Garson, J. C. Harvey, G. A. Kidwell, G. J. Klein, et al. Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/Scientific Statement From the American Heart Association and the North American Society of Pacing and Electrophysiology Circulation, September 1, 1996; 94(5): 1147 - 1166. [Full Text]